Lebrikizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis
Conditions
Atopic Dermatitis
Trial Timeline
Jan 12, 2023 → Feb 17, 2025
NCT ID
NCT05372419About Lebrikizumab
Lebrikizumab is a phase 3 stage product being developed by Eli Lilly for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05372419. Target conditions include Atopic Dermatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07006792 | Approved | Recruiting |
| NCT05372419 | Phase 3 | Completed |
| NCT05369403 | Phase 3 | Completed |
| NCT04840901 | Phase 1 | Completed |
| NCT04392154 | Phase 3 | Completed |
| NCT04250350 | Phase 3 | Completed |
| NCT04250337 | Phase 3 | Completed |
| NCT04178967 | Phase 3 | Completed |
| NCT04146363 | Phase 3 | Completed |
Competing Products
20 competing products in Atopic Dermatitis